###begin article-title 0
###xml 86 92 86 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
Prostaglandin E2 regulates B cell proliferation through a candidate tumor suppressor, Ptger4
###end article-title 0
###begin p 1
###xml 30 50 30 50 <email xmlns:xlink="http://www.w3.org/1999/xlink">xavier.gidrol@cea.fr</email>
CORRESPONDENCE Xavier Gidrol: xavier.gidrol@cea.fr
###end p 1
###begin p 2
This article is distributed under the terms of an Attribution-Noncommercial-Share Alike-No Mirror Sites license for the first six months after the publication date (see ). After six months it is available under a Creative Commons License (Attribution-Noncommercial-Share Alike 3.0 Unported license, as described at ).
###end p 2
###begin p 3
###xml 313 319 313 319 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 548 554 548 554 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 625 631 625 631 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 735 741 735 741 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 816 822 816 822 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 902 908 902 908 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 611 615 <span type="species:ncbi:10090">mice</span>
###xml 861 866 <span type="species:ncbi:9606">human</span>
B cell receptor (BCR) signaling contributes to the pathogenesis of B cell malignancies, and most B cell lymphomas depend on BCR signals for survival. Identification of genes that restrain BCR-mediated proliferation is therefore an important goal toward improving the therapy of B cell lymphoma. Here, we identify Ptger4 as a negative feedback regulator of proliferation in response to BCR signals and show that its encoded EP4 receptor is a principal molecule conveying the growth-suppressive effect of prostaglandin E2 (PGE2). Stable knockdown of Ptger4 in B cell lymphoma markedly accelerated tumor spread in mice, whereas Ptger4 overexpression yielded significant protection. Mechanistically, we show that the intrinsic activity of Ptger4 and PGE2-EP4 signaling target a similar set of activating genes, and find Ptger4 to be significantly down-regulated in human B cell lymphoma. We postulate that Ptger4 functions in B cells as a candidate tumor suppressor whose activity is regulated by PGE2 in the microenvironment. These findings suggest that targeting EP4 receptor for prostaglandin may present a novel strategy for treatment of B cell malignancies.
###end p 3
###begin p 4
Abbreviations used: BCR, B cell receptor; DLBCL, diffuse large B-cell lymphoma; GC, germinal center; miRNA, micro RNA; PGE2, prostaglandin E2; qPCR, quantitative real-time PCR; Tet, tetracycline.
###end p 4
###begin p 5
###xml 227 228 227 228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib1">1</xref>
###xml 448 449 448 449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib2">2</xref>
###xml 600 601 600 601 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib3">3</xref>
###xml 761 764 761 764 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYC</italic>
###xml 866 869 866 869 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYC</italic>
###xml 871 872 871 872 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib4">4</xref>
###xml 1381 1382 1381 1382 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib3">3</xref>
Recognition of foreign antigens by BCRs expressed on the surface of mature naive B cells triggers their massive proliferation, which is critically important for the effective defense of the organism against invading pathogens (1). Antigen-activated B cells undergo clonal expansion in dynamic structures called germinal centers (GCs) where much of the diversity of the Ig genes is generated by somatic hypermutation and class-switch recombination (2). These molecular processes require frequent DNA strand breaks that can, when deregulated, provide a rich source for the genesis of B cell lymphomas (3). For instance, the hallmark of Burkitt's lymphoma and some cases of diffuse large B cell lymphoma (DLBCL) is a reciprocal chromosomal translocation where the MYC protooncogene comes under the control of an active Ig locus, resulting in constitutive expression of MYC (4). However, although this and other translocations are thought to cause many types of B cell lymphoma, additional transforming events that override the normal mechanisms controlling B cell proliferation are needed for malignant transformation. Indeed, mutations affecting the expression level or the activity of tumor suppressor genes, as well as genomic amplifications and hypermutations of multiple protooncogenes have also been implicated in the pathogenesis of B cell lymphomas (for review see reference [3]).
###end p 5
###begin p 6
###xml 265 266 265 266 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib5">5</xref>
###xml 267 268 267 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib8">8</xref>
###xml 583 584 583 584 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib3">3</xref>
###xml 697 698 697 698 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib5">5</xref>
###xml 700 701 700 701 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib7">7</xref>
###xml 818 819 818 819 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib6">6</xref>
###xml 933 937 933 937 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PAX5</italic>
###xml 994 995 994 995 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib8">8</xref>
Despite the aggressive behavior of several types of B cell lymphoma, data gathered over the past few years have demonstrated that BCR signaling is essential for the survival of neoplastic B lymphoma cells, which also holds true for their nonmalignant counterparts (5-8). Observations that the majority of non-Hodgkin's lymphomas persistently express BCR and that IgH translocations almost never affect the functionality of Ig alleles, as well as the discovery of autoreactive BCR in certain neoplasms, indirectly suggests the need for BCR-derived survival and proliferation signals (3). Correspondingly, BCR signaling was found to promote growth of DLBCL and chronic lymphocytic leukemia B cells (5, 7), whereas follicular lymphoma B cells displayed potentiated BCR signaling versus tumor-infiltrating normal B cells (6). Most recently, a direct link between BCR signaling and B lymphomagenesis was established by demonstrating that PAX5 promotes neoplastic growth by activating BCR signaling (8). These findings, together with the recognition that the survival of many B cell tumors depends on signals provided by their microenvironment, might lead to novel treatment options for B cell lymphoma.
###end p 6
###begin p 7
###xml 150 151 150 151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib9">9</xref>
###xml 279 281 279 281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib10">10</xref>
###xml 517 519 517 519 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib11">11</xref>
###xml 901 905 <span type="species:ncbi:10090">mice</span>
###xml 910 916 <span type="species:ncbi:9606">humans</span>
More than three decades have passed since the first description of macrophage-derived PGE2 as a potent suppressor of splenic B cell colony formation (9), and it was later demonstrated that the inhibitory effect of PGE2 was caused by its direct influence on B cell proliferation (10). Further studies identified tingible body macrophages as a major source of prostaglandins in the GC microenvironment, and proposed that these scavengers of apoptotic lymphocytes may use prostaglandin to down-regulate the GC reaction (11). However, since these seminal observations, no further insight into the mechanism or relevance of the attenuating effect of PGE2 on B cell proliferation has been provided. In this study, we investigated how, mechanistically, PGE2 and its receptors may regulate B cell proliferation triggered by BCR signaling, and evaluated the potential contribution to B cell lymphoma growth in mice and humans.
###end p 7
###begin title 8
RESULTS
###end title 8
###begin title 9
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
Ptger4 is a delayed-early gene that inhibits B cell proliferation
###end title 9
###begin p 10
###xml 252 260 252 260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 A</xref>
###xml 271 279 271 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 C</xref>
###xml 282 284 282 284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib12">12</xref>
###xml 596 598 596 598 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib13">13</xref>
###xml 649 655 649 655 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 734 742 734 742 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 B</xref>
###xml 803 809 803 809 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 955 957 955 957 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib14">14</xref>
###xml 1039 1041 1039 1041 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib15">15</xref>
###xml 1151 1159 1151 1159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 B</xref>
###xml 1188 1194 1188 1194 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 1352 1363 1352 1363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1, B&#8211;D</xref>
###xml 1214 1219 <span type="species:ncbi:10090">mouse</span>
###xml 1228 1233 <span type="species:ncbi:9606">human</span>
BCR-triggered activation of mature B cells leads to transcriptional reprogramming, which can be observed by a strong induction of immediate-early genes within minutes after mitogenic stimulation, preparing a cell to quickly respond with proliferation (Fig. 1 A; see also Fig. 2 C) (12). In an attempt to identify negative regulators of B cell proliferation, we performed transcriptome analysis at 2 h after BCR stimulation and looked for putative delayed-early genes, which are generally known to function as negative feedback regulators of growth factor signaling (GEO database accession no. ) (13). Among the most strongly induced genes, we found Ptger4, whose expression kinetics appeared similar to a wave of delayed-early genes (Fig. 1 B). In addition to its high induction upon BCR cross-linking, Ptger4 also seemed interesting as a candidate regulator of B cell activation because it encodes an EP4 subtype of receptor for prostaglandin E2 (PGE2) (14), and PGE2 is known for its potent yet poorly understood immunosuppressive role (15). Notably, none of the other genes coding for PGE2 receptors showed altered expression after BCR triggering (Fig. 1 B). We found the induction of Ptger4 to be conserved in mouse A20 and human P493-6 B cell lines, and confirmed that it resulted in protein expression by Western blotting and immunofluorescence (Fig. 1, B-D and Fig. S1, available at ; see also Fig. S2).
###end p 10
###begin p 11
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 0 66 0 66 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>Ptger4</italic> is a delayed-early gene that inhibits B cell proliferation.</bold>
###xml 148 149 148 149 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 201 207 201 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 311 316 311 316 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger</italic>
###xml 336 340 336 340 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Hprt</italic>
###xml 407 413 407 413 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 430 436 430 436 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger2</italic>
###xml 454 460 454 460 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger1</italic>
###xml 482 488 482 488 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger3</italic>
###xml 498 500 498 500 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;6</sup>
###xml 794 800 794 800 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 800 803 800 803 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 808 814 808 814 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 814 817 814 817 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 71 76 <span type="species:ncbi:10090">Mouse</span>
###xml 211 216 <span type="species:ncbi:10090">mouse</span>
###xml 221 226 <span type="species:ncbi:9606">human</span>
###xml 364 369 <span type="species:ncbi:10090">mouse</span>
###xml 594 599 <span type="species:ncbi:10090">mouse</span>
###xml 818 822 <span type="species:ncbi:10090">mice</span>
###xml 879 884 <span type="species:ncbi:10090">mouse</span>
###xml 961 966 <span type="species:ncbi:10090">mouse</span>
Ptger4 is a delayed-early gene that inhibits B cell proliferation. (A) Mouse splenic B cells stimulated with (BCR) or without (ctrl) anti-IgM F(ab')2 for 72 h in culture. (B) BCR-induced expression of Ptger4 in mouse and human B cells as measured by qPCR at the indicated times. The relative abundances of each Ptger mRNA compared with Hprt transcripts in primary mouse B cells at time 0 h were as follows: Ptger4 (0.0068; 100%), Ptger2 (0.0013; 19.1%), Ptger1 (0.0009; 13.2%), and Ptger3 (2.2 x 10-6; 0.0003%). Western blotting (C) and immunofluorescence (D; at 48 h) of EP4 in BCR-stimulated mouse B cells. See Fig. S1 for higher protein loading and longer exposure immunoblot analysis, and Fig. S6 for higher quality immunofluorescence images. (E) Numbers of B cells isolated from spleen of Ptger4+/+ and Ptger4-/- mice. (F) ATP content of unstimulated and (H) BCR-stimulated mouse B cells in culture. (G) Cell cycle analysis at 60 h after BCR-triggering of mouse B cells of the indicated genotypes. Error bars are the SD of six to eight independent experiments. Bars, (A) 200 mum; (D) 100 mum. Figs. S1 and S2 are available at .
###end p 11
###begin p 12
###xml 27 33 27 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 142 148 142 148 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 148 151 148 151 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 158 160 158 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib16">16</xref>
###xml 360 375 360 375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1, E and F</xref>
###xml 484 490 484 490 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 567 573 567 573 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 650 665 650 665 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1, G and H</xref>
###xml 1229 1235 1229 1235 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 1337 1343 1337 1343 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 1460 1466 1460 1466 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 152 156 <span type="species:ncbi:10090">mice</span>
###xml 189 193 <span type="species:ncbi:10090">mice</span>
###xml 635 640 <span type="species:ncbi:10090">mouse</span>
To investigate the role of Ptger4 in peripheral B cell activation, we first examined the gross phenotypes of B cells extracted from spleen of Ptger4-/- mice (16). We observed that knockout mice consistently harboured significantly increased numbers of B cells that showed greater resistance to spontaneous cell death in vitro compared with wild-type controls (Fig. 1, E and F). In addition, cell cycle analysis and ATP content measurements revealed an augmented mitogenic response of Ptger4-deficient B cells upon BCR ligation, indicating that the early induction of Ptger4 may serve to counterbalance antigen-induced proliferation in mouse B cells (Fig. 1, G and H). To check whether the endogenously produced PGE2 may have influenced the growth of BCR-activated B cells, we examined the levels of PGE2 in culture supernatants and saw that these remained below the detection limit of 15 pg/ml during the course of the experiment (unpublished data). In addition, cotreatment with COX inhibitors indomethacin or NS-398 had no significant effect on proliferation or viability of BCR-stimulated cultures, suggesting that de novo-produced PGE2 may not be a major factor in suppressing the growth of activated wild-type compared with Ptger4-deficient B cells in culture (Fig. S3, available at ). In summary, these observations suggested that Ptger4 functions as a delayed-early gene upon BCR-triggering, and prompted us to further investigate the mechanism used by Ptger4 to attenuate BCR-signaled proliferation.
###end p 12
###begin title 13
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
Ptger4 acts as a negative feedback regulator of BCR-signaling
###end title 13
###begin p 14
###xml 33 39 33 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 139 145 139 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 219 220 219 220 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 413 419 413 419 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 421 429 421 429 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 A</xref>
###xml 943 951 943 951 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 B</xref>
###xml 977 983 977 983 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 1104 1109 1104 1109 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptprc</italic>
###xml 1148 1150 1148 1150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib17">17</xref>
###xml 1156 1160 1156 1160 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ighm</italic>
###xml 1265 1271 1265 1271 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 1271 1274 1271 1274 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1315 1323 1315 1323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 B</xref>
###xml 1437 1443 1437 1443 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 170 175 <span type="species:ncbi:10090">mouse</span>
First, to understand how lack of Ptger4 may have enhanced BCR-driven proliferation, we examined the early transcriptional response of both Ptger4-deficient and wild-type mouse B cells to stimulation with anti-IgM F(ab')2 in culture. We were surprised by the regulation of genes known to affect lymphocyte proliferation, which showed two functionally coherent groups of genes defined by the presence or absence of Ptger4 (Fig. 2 A). In line with the aforementioned observations, 11 out of 13 genes (85%) that had higher expression levels in knockout relative to wild-type B cells were found to promote proliferation, whereas all (5 out of 5) genes overexpressed in wild-types had an inhibitory role. Surprisingly, signaling through the BCR in wild-type cells resulted in a profound down-regulation of most genes encoding components of the proximal BCR-signaling cascade itself, suggesting the existence of a potent negative feedback mechanism (Fig. 2 B). Although triggering of Ptger4-deficient B cells also repressed the majority of these genes, several crucial genes of the upper BCR pathway, including Ptprc coding for CD45 (also known as B220) (17) and Ighm coding for the immunoglobulin heavy chain of the B cell receptor itself, were induced nearly twofold in Ptger4-/- cells compared with wild-type controls (Fig. 2 B). This indicates that by maintaining the relatively high expression of certain signaling components, the lack of Ptger4 may prolong the duration of signaling via the BCR, cumulatively delivering a stronger proliferative stimulus.
###end p 14
###begin p 15
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 0 71 0 71 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>Ptger4</italic> is a negative feedback regulator of BCR-triggered proliferation.</bold>
###xml 413 419 413 419 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 419 422 419 422 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 839 845 839 845 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 845 848 845 848 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 926 932 926 932 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 990 994 990 994 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Egr1</italic>
###xml 996 999 996 999 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fos</italic>
###xml 1005 1008 1005 1008 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jun</italic>
###xml 1151 1157 1151 1157 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 1177 1183 1177 1183 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 1322 1330 1322 1330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 A</xref>
###xml 1610 1611 1609 1610 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
Ptger4 is a negative feedback regulator of BCR-triggered proliferation. (A) Relative expression values and functions of genes known to affect lymphocyte proliferation, according to Ingenuity Pathway Analysis database (IPA; see URLs in Materials and methods). For each gene, the expression ratio in BCR-stimulated (BCR) versus control (ctrl) sample at 2 h is shown (filled bars, wild-type [wt] B cells; open bars, Ptger4-/- [KO] B cells). Genes were ranked according to their absolute ratios in descending order. (B) Proximal part of the BCR-signaling canonical pathway. The molecules whose encoding genes showed at least a twofold change in expression upon BCR-triggering of wild-type B cells are colored (green, down-regulation; red, up-regulation). Black arrows indicate genes that showed at least a 50% difference in expression between Ptger4-/- and wild-type B cells. Numbers indicate fold induction caused by the lack of Ptger4. (C) BCR-induced expression of the immediate-early genes Egr1, Fos, and Jun in A20 cell line. (D) A20 cells were cotransfected with plasmids encoding GFP cocistronic with nontargeting miRNA (miCTRL) or miRNA targeting Ptger4 (miPtger4b) or the Ptger4 ORF, together with the indicated luciferase reporter plasmid. The knockdown efficiency was similar to that achieved in stable cell lines (Fig. 3 A). Luminescence was determined after BCR stimulation as detailed in Materials and methods. Error bars are the SD of triplicates. To exclude the possibility of saturation, the assay for EGR1 and CRE activity was also performed at a lower concentration (5 mug/ml) of anti-IgG F(ab')2 (Fig. S4). Fig. S4 is available at .
###end p 15
###begin p 16
###xml 66 72 66 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 125 129 125 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cdk4</italic>
###xml 131 137 131 137 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plagl2</italic>
###xml 143 148 143 148 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nfkb1</italic>
###xml 207 209 207 209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib18">18</xref>
###xml 210 212 210 212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib20">20</xref>
###xml 226 230 226 230 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cd74</italic>
###xml 235 241 235 241 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H2-DMa</italic>
###xml 501 503 501 503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib21">21</xref>
###xml 505 507 505 507 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib22">22</xref>
###xml 474 479 <span type="species:ncbi:9606">human</span>
Among the genes most significantly up-regulated in the absence of Ptger4, we found three potent cell cycle-regulating genes, Cdk4, Plagl2, and Nfkb1, which are all known to promote G1 to S phase transition (18-20), as well as Cd74 and H2-DMa, which are both members of the MHC class II family (Table S1, available at ). Notably, CD74 has been shown to promote B cell lymphoma progression, and an anti-CD74 antibody is currently being clinically evaluated for the therapy of human B cell malignancies (21, 22).
###end p 16
###begin p 17
###xml 110 112 110 112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib23">23</xref>
###xml 163 169 163 169 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 436 444 436 444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 B</xref>
###xml 642 644 642 644 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib24">24</xref>
###xml 646 648 646 648 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib25">25</xref>
Because B cells use antigen-presenting MHC class II molecules to attract activating help from helper T cells (23), endogenous control of the MHC-encoding genes by Ptger4 may thus provide another means to keep B cell activation in check. Indeed, as we demonstrate in this study, signaling via the EP4 receptor potently repressed the expression of multiple MHC components essential for effective antigen presentation by B cells (see also Fig. 5 B). Interestingly, it has been reported that PGE2 and EP2/EP4 agonists significantly inhibit the expression of MHC class II molecules in B lymphocytes stimulated with IL-4 and/or lipopolysaccharide (24, 25), suggesting that the inhibition of MHC class II by EP4 may occur independently of the stimulus used to activate B cells.
###end p 17
###begin p 18
###xml 37 43 37 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 162 177 162 177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2, C and D</xref>
###xml 230 236 230 236 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 372 378 368 374 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 378 381 374 377 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 481 486 473 478 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Traf5</italic>
###xml 488 493 480 485 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nfkb1</italic>
###xml 495 501 487 493 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nfkbie</italic>
###xml 507 511 499 503 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fbi1</italic>
###xml 587 589 579 581 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib20">20</xref>
###xml 591 593 583 585 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib26">26</xref>
###xml 635 641 627 633 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 764 770 752 758 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 988 996 972 980 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 D</xref>
###xml 999 1001 983 985 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib27">27</xref>
###xml 1063 1069 1047 1053 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 1218 1226 1202 1210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 D</xref>
###xml 1256 1258 1240 1242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib28">28</xref>
###xml 1260 1262 1244 1246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib29">29</xref>
###xml 1300 1306 1284 1290 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
To verify the regulatory function of Ptger4 in BCR-driven gene transcription, we focused on a set of immediate-early genes induced by antigen-receptor signaling (Fig. 2, C and D). Transient micro RNA (miRNA)-mediated knockdown of Ptger4 in the A20 B cell lymphoma line resulted in increased transcriptional activity of NF-kappaB, in line with the observation from primary Ptger4-/- B cells, where genes coding for essential components of the NF-kappaB signaling pathway, including Traf5, Nfkb1, Nfkbie, and Fbi1, have been found significantly induced over controls (GEO accession no. ) (20, 26). In contrast, ectopic expression of the Ptger4 ORF region repressed BCR-driven transcription through NF-kappaB, complementing the results from loss-of-function studies. Ptger4 exerted a similar inhibitory effect on transcriptional activity of the AP-1 components FOS and JUN, and potently decreased expression from IL-2 promoter known to contain critically important AP-1 and NF-kappaB sites (Fig. 2 D) (27). On the other hand, neither silencing nor overexpression of Ptger4 influenced transcriptional activity of EGR1 or transcription through cAMP-response element (CRE), both of which greatly increase upon BCR ligation (Fig. 2 D and Fig. S4, available at ) (28, 29). Together, these data indicate that Ptger4 negatively regulates BCR-mediated gene expression and B cell proliferation, primarily by inhibiting NF-kappaB and AP-1 transcriptional activity.
###end p 18
###begin title 19
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 42 47 <span type="species:ncbi:10090">mouse</span>
Ptger4 is a candidate tumor suppressor in mouse B cell lymphoma
###end title 19
###begin p 20
###xml 11 17 11 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 17 20 17 20 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 148 154 148 154 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 307 313 307 313 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 339 345 339 345 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 487 493 487 493 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 534 542 534 542 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 A</xref>
###xml 820 826 820 826 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 893 901 893 901 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 B</xref>
###xml 1203 1209 1203 1209 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 1209 1212 1209 1212 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1261 1267 1261 1267 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 715 720 <span type="species:ncbi:9606">human</span>
###xml 804 809 <span type="species:ncbi:10090">mouse</span>
###xml 814 819 <span type="species:ncbi:9606">human</span>
###xml 938 943 <span type="species:ncbi:9606">human</span>
###xml 1289 1294 <span type="species:ncbi:10090">mouse</span>
###xml 1299 1304 <span type="species:ncbi:9606">human</span>
As primary Ptger4-/- B cells resisted rapid cell death in vitro in the absence of activating stimuli, we next set out to determine how altering the Ptger4 gene dosage would affect B cell growth and survival. To this end, we designed lentiviral vectors containing either GFP cocistronic with miRNA targeting Ptger4 (miPtger4) or the cloned Ptger4 ORF region to generate stable A20 B cell lines. Quantitative PCR (qPCR) and immunoblotting confirmed the efficiency of the stably integrated Ptger4 knockdown and overexpressing cassettes (Fig. 3 A). Interestingly, although the introduced changes did not seem to influence the in vitro growth of A20 cells, which have a doubling time of <12 h, the slower growing P493-6 human B cell line was significantly impacted by a silencing construct that targeted both mouse and human Ptger4 and achieved comparable gene knockdown levels in both cell lines (Fig. 3 B and unpublished data). The modified human B cells showed a similar rate of proliferation at low cell concentrations compared with controls, but later resisted overgrowth and reached about twice the density of viable control cells in the medium. This is in agreement with increased ex vivo survival of Ptger4-/- cells and indicates that reducing the levels of Ptger4 enhances survival of mouse and human B cells.
###end p 20
###begin p 21
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 0 50 0 50 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>Ptger4</italic> is a candidate tumor suppressor in B cells.</bold>
###xml 155 161 155 161 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 421 422 421 422 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 726 727 726 727 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 396 400 <span type="species:ncbi:10090">mice</span>
###xml 480 484 <span type="species:ncbi:10090">mice</span>
###xml 752 757 <span type="species:ncbi:10090">mouse</span>
Ptger4 is a candidate tumor suppressor in B cells. (A) Stable A20 cell lines were generated by lentiviral infection as described in Materials and methods. Ptger4 expression was determined by qPCR and confirmed by Western blotting. (B) ATP content and viability of stable P493-6 cell lines in culture. RLU, relative luminescence units. Error bars are the SD of triplicates. (C) Survival of BALB/c mice injected with 2 x 105 A20 cells stably expressing the indicated constructs. 10 mice were used to derive each survival curve. Logrank test comparing two survival curves was used to derive P values, as indicated. (D) Tumor formation at the site of injection of the indicated stable A20 cell line at 20 d after injection (5 x 105 cells were injected per mouse; top), and a fluorescence micrograph showing GFP-expressing tumor tissue in the eye region (bottom).
###end p 21
###begin p 22
###xml 125 131 125 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 404 412 404 412 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 C</xref>
###xml 788 794 788 794 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 946 954 946 954 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 C</xref>
###xml 1001 1007 1001 1007 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 1502 1508 1502 1508 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 1531 1539 1531 1539 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 D</xref>
###xml 1584 1590 1584 1590 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 1664 1670 1664 1670 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 264 268 <span type="species:ncbi:10090">mice</span>
###xml 613 617 <span type="species:ncbi:10090">mice</span>
###xml 877 881 <span type="species:ncbi:10090">mice</span>
###xml 1147 1151 <span type="species:ncbi:10090">mice</span>
We then asked whether vigorous in vitro proliferation of A20 cells could have obscured the effect of over- or underexpressed Ptger4 by setting up a more sensitive in vivo system. Because A20 cells are known to induce tumor formation when introduced into syngeneic mice, we injected 200,000 viable cells from each of the generated A20 lines in the BALB/c strain and monitored tumor development over time (Fig. 3 C). Stable coexpression of GFP in the injected cells allowed us to easily track tumor origin by fluorescence microscopy of the dissected or intact tumor tissue. Stunningly, although most of the control mice injected with nontargeting miRNA (miCTRL)-carrying cells succumbed to disseminated B-lymphoma development over the first two-month period, as expected, overexpression of Ptger4 yielded significant protection against lymphoma spread, and the majority (70%) of mice survived beyond the monitoring period with no adverse symptoms (Fig. 3 C). In contrast, A20 cells with stably silenced Ptger4 potently aggravated tumor burden, which frequently manifested as liver and neck region metastasis, as well as hind limb paralysis, and the mice quickly became terminally ill. Additionally, the more efficient miRNA, miPtger4b, triggered a more severe phenotype than the less efficient miPtger4a, as was also evident from a separate experiment in which a higher number of injected cells induced tumor formation at the site of injection in the eye, with the size of the tumor corresponding to the Ptger4 knockdown efficiency (Fig. 3 D). Collectively, these data demonstrate that Ptger4 negatively regulates B cell survival and proliferation, and suggest that Ptger4 may function as a tumor suppressor in B cells.
###end p 22
###begin title 23
PGE2 suppresses B cell proliferation by targeting the EP4 receptor
###end title 23
###begin p 24
###xml 81 87 81 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 337 339 337 339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib10">10</xref>
###xml 341 343 341 343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib30">30</xref>
###xml 344 346 344 346 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib32">32</xref>
###xml 460 466 460 466 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 528 533 528 533 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger</italic>
###xml 542 550 542 550 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 B</xref>
###xml 886 894 886 894 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 A</xref>
###xml 1099 1107 1099 1107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 B</xref>
###xml 1522 1530 1522 1530 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 C</xref>
We next examined the potential physiological relevance of the inhibitory role of Ptger4 on B cell growth by focusing on the effects of the only known but extremely potent endogenous ligand for EP4 receptor, prostaglandin E2 (PGE2). Several reports have documented a repressive role of PGE2 on immune responses and B cells in particular (10, 30-32), but no study to date has identified the exact mechanism by which this inhibition occurs. Because we identified Ptger4 as a delayed-early gene and the only BCR-induced gene of the Ptger series (Fig. 1 B), we speculated that the EP4 receptor may be important for conveying the growth-regulatory actions of PGE2 in B cells. We first checked the influence of PGE2 on BCR-triggered proliferation of wild-type cells in vitro and saw that PGE2 at a concentration as low as 1 nM effectively prevented B cell cluster formation and proliferation (Fig. 4 A). In contrast, EP4-null B cells were completely insensitive to the inhibition by PGE2, forming massive clusters of proliferating cells similar to the vehicle-treated controls, even at high doses of PGE2 (Fig. 4 B). This strongly suggested that EP4 was the major, if not the only receptor transmitting the PGE2-delivered signal to block B cell growth. In addition, treatment with the EP4-specific agonist PGE1-OH faithfully mimicked the inhibitory activity of PGE2 in wild-type, but not EP4-null, cells, as opposed to stimulating the closest EP4-related receptor, EP2, which did not influence proliferation of either cell type (Fig. 4 C).
###end p 24
###begin p 25
###xml 0 87 0 87 <bold xmlns:xlink="http://www.w3.org/1999/xlink">The suppressive effect of PGE2 on B cell proliferation is mediated by the EP4 receptor.</bold>
###xml 87 93 87 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 93 96 93 96 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 105 111 105 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 111 114 111 114 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 188 189 188 189 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 561 563 560 562 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib56">56</xref>
###xml 703 709 702 708 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 709 712 708 711 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 717 723 716 722 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 723 726 722 725 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 541 546 <span type="species:ncbi:10090">mouse</span>
###xml 727 732 <span type="species:ncbi:10090">mouse</span>
The suppressive effect of PGE2 on B cell proliferation is mediated by the EP4 receptor.Ptger4+/+ (A) and Ptger4-/- (B) splenic B cells were incubated in vitro for 60 h with anti-IgM F(ab')2 and cotreated with PGE2 at the concentrations as indicated (ctrl, vehicle-treated control). Bar, 200 mum. (C) BCR-stimulated splenic B cells were cotreated as indicated for 60 h, followed by determination of ATP content. Final concentrations of PGE1-OH and AH-13205 were adjusted to compensate for the differences between inhibitory constants for the mouse EP4 receptor (56). RLU, relative luminescence units. Error bars are the SD of triplicates. (D) The CFSE staining method was used to follow proliferation of Ptger4+/+ and Ptger4-/- mouse B cells. Flow cytometry analysis of viable cells is shown (see Materials and methods).
###end p 25
###begin p 26
###xml 175 181 175 181 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 181 184 181 184 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 189 195 189 195 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 195 198 195 198 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 504 510 504 510 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 510 513 510 513 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 982 990 982 990 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 C</xref>
###xml 1137 1145 1137 1145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 D</xref>
###xml 1184 1186 1184 1186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib10">10</xref>
###xml 1348 1354 1348 1354 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 1910 1918 1910 1918 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 D</xref>
To more closely examine how triggering of EP4 by PGE2-affected B cell activation, we used time-lapse microscopy to follow cell growth and cluster development of BCR-triggered Ptger4+/+ and Ptger4-/- B cells in the presence of PGE2 over several days. Although the two cell populations did not differ during the initial phase (the first 18-24 h) of cluster formation, the effect of PGE2 became progressively more apparent, as the wild-type cells were less efficient at forming bigger groups of cells. Once Ptger4-/- cells entered a cluster, they stayed associated with it until the activation reaction was terminated, as opposed to wild-type cells, which dynamically shuttled in and out of clusters, resulting in a smaller net size of the clusters and in more cells found dispersed throughout the culture plate (Videos S1 and S2, available at ). Notably, this time-dependent activity of PGE2 was in line with the kinetics of BCR-induced EP4 expression, as revealed by immunoblotting (Fig. 1 C). To discern the impact of signaling through EP4 on cell proliferation, we used the CFSE method to follow cell division of BCR-activated B cells (Fig. 4 D). In agreement with a previous study (10), PGE2 allowed wild-type B cells to undergo only one round of cell division, but significantly inhibited further proliferation of daughter B cells. In contrast, Ptger4-deficient cells displayed complete protection against the proliferation-limiting effects of PGE2, confirming the suggestion that EP4 is the primary molecule mediating the negative influence of PGE2 on B cell activation. The addition of PGE2 diminished the viability of activated wild-type B cells in a time- and dose-dependent manner (Fig. S5), suggesting that PGE2 signaling via the EP4 receptor promoted the apoptosis of replicating progeny. The greater proportion of undivided cells at 96 h compared with 60 h in cultures supplemented with 10 nM PGE2 (Fig. 2 D) is thus a likely consequence of a preferential death of the divided population at the later time point.
###end p 26
###begin title 27
PGE2-EP4 signaling results in general repression of activating genes
###end title 27
###begin p 28
###xml 726 734 726 734 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 A</xref>
###xml 1087 1093 1075 1081 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 1093 1096 1081 1084 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
We next asked how, mechanistically, PGE2-EP4 signaling antagonizes the proliferative burst of B cells triggered by antigen receptor cross-linking. Therefore, we inspected the transcriptional status of activated wild-type B cells incubated with or without PGE2 in comparison to EP4-null cells at 24 h after BCR triggering, a time point at which the inhibited phenotype started to become apparent and when EP4 protein was first readily detected by immunoblotting. Interestingly, of the 263 genes whose expression was altered by more than twofold in wild-type B cells because of the presence of PGE2, 91% (240 genes) were down-regulated, indicating a general repressive effect of PGE2 on gene transcription in activated B cells (Fig. 5 A). To the contrary, only 10 of the approximately22,000 genes examined were either induced or repressed in knockout cells, suggesting that EP4 was indeed the primary receptor through which PGE2 exerted its attenuation of the BCR-induced response. This finding was confirmed by an independent direct comparison of activated and PGE2-treated wild-type and Ptger4-/- B cells, which revealed EP4-mediated 85% (527 out of 623 genes affected) attenuation of gene transcription (unpublished data).
###end p 28
###begin p 29
###xml 0 69 0 69 <bold xmlns:xlink="http://www.w3.org/1999/xlink">PGE2&#8211;EP4 signaling results in general repression of activating genes.</bold>
###xml 124 130 124 130 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 130 133 130 133 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 141 147 141 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 147 150 147 150 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 582 588 582 588 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 588 591 588 591 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 599 605 599 605 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 605 608 605 608 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 655 661 655 661 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 661 664 661 664 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 672 678 672 678 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 678 681 678 681 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
PGE2-EP4 signaling results in general repression of activating genes. (A) Genes regulated at least twofold in BCR-triggered Ptger4+/+ and/or Ptger4-/- B cells by 1 nM PGE2 at 24 h. For each genetic background, log expression ratios of PGE2-treated (BCR+PGE2) versus vehicle-treated (BCR+vehicle) activated B cells are shown for each gene. The x axis denotes number of genes. (B) Genes that are induced when EP4 is absent are repressed when EP4 is abundant and activated. Shown are the log expression ratios of 128 genes commonly regulated in conditions designated as "lack of EP4" (Ptger4-/- versus Ptger4+/+ BCR-triggered B cells at 2 h) and "PGE2-EP4" (Ptger4+/+ versus Ptger4-/- BCR-triggered and 1 nM PGE2 cotreated B cells at 24 h). The identity of genes and their values are listed in Table S2. (C, D) Genes from the "PGE2-EP4" condition in (B) were connected using the IPA knowledge database. Two most significant and coherent networks consisted of genes associated with the NF-kB pathway (C) and MHC class I and II molecules (D). Green, down-regulated genes; red, up-regulated genes.
###end p 29
###begin p 30
###xml 177 183 165 171 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 183 186 171 174 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 230 238 218 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 B</xref>
###xml 915 930 899 914 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5, C and D</xref>
###xml 1004 1010 988 994 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
We then examined the identity of the genes regulated by the PGE2-EP4 pathway, and observed that a significant proportion (approximately21%) of these genes were also impacted in Ptger4-/- B cells early after triggering of the BCR (Fig. 5 B and Table S2, available at ). However, genes that changed expression in both models had a reciprocal pattern of change; genes that were up-regulated because of the lack of EP4 were down-regulated in conditions where EP4 was abundant and stimulated by PGE2, confirming that this set of genes was specifically controlled by the EP4 receptor. PGE2-EP4 signaling most profoundly attenuated the expression of several genes coding for molecules of the NF-kappaB pathway, ribosomal proteins, translation-initiation factors, and ATP-producing molecules, as well as components of the MHC and (immuno)proteasome, most of which are known to be mandatory for efficient B cell activation (Fig. 5, C and D, and Table S2). These data validate and complement the observations from Ptger4-deficient B cells, indicating that EP4 functions to prime the inhibitory activity of its endogenous ligand PGE2 by repressing transcription of a functionally coherent set of activating genes, eventually leading to a systemic attenuation of B cell proliferation.
###end p 30
###begin title 31
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
Ptger4 antagonizes GC B cell development
###end title 31
###begin p 32
###xml 160 166 160 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 263 265 263 265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib33">33</xref>
###xml 267 269 267 269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib34">34</xref>
###xml 355 361 355 361 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 437 443 437 443 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 785 791 785 791 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 791 794 791 794 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 933 939 933 939 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 1232 1234 1232 1234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib35">35</xref>
###xml 1387 1393 1387 1393 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 1393 1396 1393 1396 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1532 1534 1532 1534 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib31">31</xref>
###xml 1557 1559 1557 1559 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib36">36</xref>
###xml 246 250 <span type="species:ncbi:10090">mice</span>
###xml 255 261 <span type="species:ncbi:9606">humans</span>
###xml 795 799 <span type="species:ncbi:10090">mice</span>
###xml 1107 1113 <span type="species:ncbi:9606">humans</span>
###xml 1397 1401 <span type="species:ncbi:10090">mice</span>
To verify the implications of our findings beyond the model of in vitro BCR-stimulated cells, we first screened the published data for potential differences in Ptger4 expression levels between naive follicular B cells and activated GC B cells in mice and humans (33, 34). In accord with the expectations, GC B cells exhibited profoundly reduced levels of Ptger4 compared with naive controls, confirming the in vitro observation that low Ptger4 expression favors B cell proliferation (Fig. S6, A and B, available at ). We then examined the expression of EP4 protein and saw that GC B cells expressed it at a much lower level compared with naive B cells, supporting the data from the aforementioned transcriptional analyses (Fig. S6 C). Furthermore, the analysis of GC B cell content in Ptger4-/- mice immunized with a T cell-dependent antigen found a significant increase compared with wild-type controls, indicating that the lack of Ptger4 was causative for the enhanced activation of B cells in vivo (Fig. S6 D). The importance of these findings is underscored by the fact that many B cell malignancies in humans show expression patterns of differentiation markers and global gene-expression profiles characteristic of GC B cells (35), thus most types of B cell lymphoma are thought to originate from GC B cells. It should be noted, however, that the higher proportion of GC B cells in Ptger4-/- mice may have resulted, at least in part, as a consequence of altered functioning of other EP4-expressing cell types, such as T cells (31) and dendritic cells (36), which also participate in T cell-dependent immune responses.
###end p 32
###begin title 33
###xml 18 21 18 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYC</italic>
###xml 37 43 37 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTGER4</italic>
###xml 47 52 <span type="species:ncbi:9606">human</span>
The protooncogene MYC down-regulates PTGER4 in human B cell lymphomas
###end title 33
###begin p 34
###xml 32 38 32 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTGER4</italic>
###xml 99 105 99 105 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTGER4</italic>
###xml 191 193 191 193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib37">37</xref>
###xml 236 242 236 242 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTGER4</italic>
###xml 418 424 418 424 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTGER4</italic>
###xml 480 488 480 488 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6 A</xref>
###xml 570 576 570 576 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTGER4</italic>
###xml 626 629 626 629 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYC</italic>
###xml 678 681 678 681 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYC</italic>
###xml 716 719 716 719 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYC</italic>
###xml 867 869 867 869 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib38">38</xref>
###xml 976 979 976 979 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYC</italic>
###xml 1026 1029 1026 1029 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYC</italic>
###xml 1067 1070 1067 1070 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYC</italic>
###xml 1103 1105 1103 1105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib39">39</xref>
###xml 1186 1192 1186 1192 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTGER4</italic>
###xml 1206 1209 1206 1209 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYC</italic>
###xml 1238 1244 1238 1244 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTGER4</italic>
###xml 1282 1285 1282 1285 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYC</italic>
###xml 1318 1324 1318 1324 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTGER4</italic>
###xml 1356 1359 1356 1359 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYC</italic>
###xml 1370 1376 1370 1376 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTGER4</italic>
###xml 1389 1397 1389 1397 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6 B</xref>
###xml 1443 1446 1443 1446 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYC</italic>
###xml 1451 1457 1451 1457 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTGER4</italic>
###xml 1491 1497 1491 1497 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTGER4</italic>
###xml 1736 1739 1736 1739 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYC</italic>
###xml 1756 1758 1756 1758 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib38">38</xref>
###xml 1824 1830 1824 1830 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTGER4</italic>
###xml 1878 1881 1878 1881 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYC</italic>
###xml 1925 1928 1925 1928 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYC</italic>
###xml 2063 2071 2063 2071 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6 C</xref>
###xml 2137 2143 2137 2143 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTGER4</italic>
###xml 2186 2189 2186 2189 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYC</italic>
###xml 2233 2239 2233 2239 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTGER4</italic>
###xml 2337 2343 2337 2343 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTGER4</italic>
###xml 2490 2496 2490 2496 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTGER4</italic>
###xml 42 47 <span type="species:ncbi:9606">human</span>
###xml 450 455 <span type="species:ncbi:9606">human</span>
###xml 591 596 <span type="species:ncbi:9606">human</span>
###xml 895 900 <span type="species:ncbi:9606">human</span>
###xml 1560 1565 <span type="species:ncbi:9606">human</span>
###xml 2147 2152 <span type="species:ncbi:9606">human</span>
###xml 2557 2562 <span type="species:ncbi:9606">human</span>
To investigate the relevance of PTGER4 to human disease, we first looked for altered expression of PTGER4 in normal versus malignant B cell populations by mining the GEO expression database (37). Interestingly, the analysis showed that PTGER4 is markedly down-regulated in the most commonly occurring, aggressive form of B cell malignancy, DLBCL, indicating that the reduction of proliferation-attenuating function of PTGER4 may indeed contribute to human B cell lymphoma growth (Fig. 6 A). We then asked about the possible mechanism leading to the observed decrease in PTGER4 expression in human neoplasia by focusing on the MYC gene. Because of chromosomal breakpoints at the MYC locus, increased transcription of MYC is a frequent cause of B lymphomagenesis, and has been associated with an adverse clinical outcome in several cases of aggressive B cell lymphoma (38). To that end, we used a human B cell line (P493-6) carrying a conditional tetracycline (Tet)-regulatable MYC allele that allows for abundant expression of MYC in the absence of Tet, but only weak MYC expression when Tet is present (39). We saw that the presence of Tet markedly influenced BCR-induced expression of PTGER4; in the high-MYC condition, the induction of PTGER4 was moderate, whereas low amounts of MYC transcripts greatly facilitated PTGER4 up-regulation, suggesting that MYC represses PTGER4 expression (Fig. 6 B). To examine whether the association between MYC and PTGER4 is relevant in vivo, we selected PTGER4 and several known tumor suppressors with established roles in human B cell lymphoma, and examined their expression in clinical cases of Burkitt's lymphoma, DLBCL, and some other types of mature aggressive B cell lymphomas with or without MYC translocations (38). We observed that this set of tumor-suppressor genes, including PTGER4, was coordinately down-regulated in cases with MYC translocations compared with cases without MYC translocations, irrespective of morphological, clinical, or immunohistochemical characteristics of the investigated B cell lymphomas (Fig. 6 C). These findings are consistent with a tumor-suppressive role of PTGER4 in human B cell cancer, and implicate the MYC oncogene as a potent negative regulator of PTGER4 expression. Although our data allow for a causative correlation, the extent to which the reduced PTGER4 expression contributes to the origin of these malignancies remains speculative, and further studies will be required to evaluate the potential of PTGER4 and its encoded EP4 receptor as a target for the therapy of human B cell lymphoma.
###end p 34
###begin p 35
###xml 0 3 0 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYC</italic>
###xml 37 43 37 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTGER4</italic>
###xml 0 69 0 69 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>MYC</italic> down-regulates the expression of <italic>PTGER4</italic> in human B cell lymphoma.</bold>
###xml 74 80 74 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTGER4</italic>
###xml 196 198 196 198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib30">30</xref>
###xml 254 257 254 257 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYC</italic>
###xml 294 300 294 300 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTGER4</italic>
###xml 425 431 425 431 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTGER4</italic>
###xml 491 494 491 494 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYC</italic>
###xml 570 576 570 576 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTGER4</italic>
###xml 685 688 685 688 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYC</italic>
###xml 704 706 704 706 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib38">38</xref>
###xml 921 923 921 923 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib57">57</xref>
###xml 1128 1131 1128 1131 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYC</italic>
###xml 1268 1274 1268 1274 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTGER4</italic>
###xml 1451 1454 1451 1454 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYC</italic>
###xml 1459 1465 1459 1465 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTGER4</italic>
###xml 47 52 <span type="species:ncbi:9606">human</span>
###xml 116 121 <span type="species:ncbi:9606">human</span>
###xml 308 313 <span type="species:ncbi:9606">human</span>
###xml 657 662 <span type="species:ncbi:9606">human</span>
###xml 843 848 <span type="species:ncbi:9606">human</span>
MYC down-regulates the expression of PTGER4 in human B cell lymphoma. (A) PTGER4 is significantly down-regulated in human DLBCL cells relative to normal B cells. Data were analyzed from reference 30. The P value from Wilcoxon rank sum test is shown. (B) MYC inhibits BCR-triggered induction of PTGER4 in the human P493-6 B cell line. Cells were incubated with (Tet ON) or without Tet (Tet OFF) for 3 d, and the expression of PTGER4 after BCR-triggering was determined by qPCR. Tet-dependent MYC expression is shown in the insert. Error bars are s.d. of triplicates. (C) PTGER4 and several known tumor suppressors are coordinately down-regulated in multiple human B cell lymphomas with MYC translocation (38). Data were analyzed from a comprehensive study, including samples of 220 mature aggressive B cell lymphomas using the algorithm of the human cancer-profiling database Oncomine (see URLs in Materials and methods) (57). Shown is the heat map comprising the microarray results, where red indicates induction of genes and blue indicates repression of genes. Samples were classified according to the presence (or absence) of MYC translocations, as indicated. Genes showing the lowest P values were selected and ranked in ascending order. The selected genes, except PTGER4, have been described as tumor suppressors in B cell lymphoma according to Pubmed (see URLs in Materials and methods). The scheme om the bottom presents the interaction between MYC and PTGER4 in a lymphoma-relevant context.
###end p 35
###begin title 36
DISCUSSION
###end title 36
###begin p 37
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger</italic>
###xml 301 307 301 307 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 516 522 516 522 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
Ptger series of genes have traditionally been viewed and studied in light of the interactions of their encoded receptors with PGE2 as the natural ligand, whereas kinetics of gene expression or the intrinsic functioning of EP receptor subtypes has received little attention. In this study, we identify Ptger4 as a typical delayed-early gene negatively regulating the robust proliferative response of B cells to antigen receptor triggering and use transcriptome analysis to delineate the attenuating mechanism used by Ptger4.
###end p 37
###begin p 38
###xml 21 27 21 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 201 207 201 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 626 632 626 632 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 738 744 738 744 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 913 915 913 915 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib40">40</xref>
###xml 917 919 917 919 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib41">41</xref>
###xml 1058 1060 1058 1060 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib42">42</xref>
###xml 1324 1326 1324 1326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib41">41</xref>
###xml 1328 1330 1328 1330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib42">42</xref>
###xml 1600 1602 1600 1602 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib10">10</xref>
###xml 1604 1606 1604 1606 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib40">40</xref>
###xml 1608 1610 1608 1610 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib41">41</xref>
###xml 1612 1614 1612 1614 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib43">43</xref>
###xml 1615 1617 1615 1617 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib45">45</xref>
###xml 1718 1719 1718 1719 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib9">9</xref>
###xml 1721 1723 1721 1723 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib24">24</xref>
###xml 1725 1727 1725 1727 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib46">46</xref>
###xml 1729 1731 1729 1731 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib47">47</xref>
###xml 1815 1817 1815 1817 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib10">10</xref>
###xml 1834 1836 1834 1836 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib43">43</xref>
###xml 1852 1854 1852 1854 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib45">45</xref>
###xml 1892 1894 1892 1894 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib41">41</xref>
###xml 307 312 <span type="species:ncbi:10090">mouse</span>
###xml 654 659 <span type="species:ncbi:9606">human</span>
###xml 766 771 <span type="species:ncbi:10090">mouse</span>
###xml 776 781 <span type="species:ncbi:9606">human</span>
###xml 898 903 <span type="species:ncbi:9606">human</span>
###xml 991 996 <span type="species:ncbi:10090">mouse</span>
###xml 1309 1314 <span type="species:ncbi:10090">mouse</span>
###xml 1411 1416 <span type="species:ncbi:10090">mouse</span>
###xml 1585 1590 <span type="species:ncbi:9606">human</span>
###xml 1690 1695 <span type="species:ncbi:10090">mouse</span>
###xml 1924 1929 <span type="species:ncbi:9606">human</span>
###xml 2180 2186 <span type="species:ncbi:9606">humans</span>
The observation that Ptger4 knockout B cells display a more activated genotype compared with wild-type controls early after BCR-stimulation in vitro suggests an inherent growth-suppressing activity of Ptger4 that is independent of PGE2-EP4 interactions. This is supported by the finding that BCR-stimulated mouse B cells do not secrete any substantial amounts of PGE2 in culture and that incubation of wild-type B cells with COX inhibitors to block the potential PGE2 biosynthesis does not augment proliferation of activated B cells, excluding the possible influence of de novo-produced PGE2. In addition, stable knockdown of Ptger4 promoted growth of a human B cell line in culture, suggesting that the intrinsic growth-limiting role of Ptger4 is conserved between mouse and human B cells. Although there is evidence for the secretion of relatively high amounts of PGE2 by quiescent and activated human B cells (40, 41), we are not aware of any studies supporting the production of PGE2 by mouse B lymphocytes, with the exception of a study by Graf et al. (42) showing that a biphenotypic B/macrophage population of cells produces substantial amounts of PGE2 upon stimulation with lipopolysaccharide, CD40, or BCR ligand. In contrast, it has been noted that the expression of COX-1 and -2 is not observed in mouse B cells (41, 42), and the lack of induction of COX-2 is confirmed by our microarray analysis of mouse B cells after BCR engagement (GSE9215 and GSE9847). Interestingly, although controversy exists regarding the net effect of PGE2 on proliferative responses of activated human B cells (10, 40, 41, 43-45), there appears to be a consensus on the inhibitory function of PGE2 on mouse B cell proliferation (9, 24, 46, 47). Depending on the mitogenic stimulus studied, reports have documented inhibition (10), no influence (43), stimulation (45), or concentration-dependent effect (41) of PGE2 on proliferation of human B cells. It is possible that the various stimuli differently regulate the expression of or signaling through each of the four distinct PGE2 receptors, some of them with opposing functions, thus critically influencing the net result of PGE2 action on humans B cells. Further studies will be required to show whether PGE2-EP4 signaling is inhibitory in each of these B cell-activating conditions.
###end p 38
###begin p 39
###xml 45 51 45 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 124 130 124 130 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 514 520 510 516 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 655 661 651 657 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
Two main observations lead us to assume that Ptger4 acts as a feedback regulator to attenuate BCR-signaling pathway. First, Ptger4 counteracted the transcriptional activity of early-induced NF-kappaB and AP-1 complexes, which are both essential for propagating B cell growth and proliferation, and, second, it facilitated down-regulation of several proximal BCR-signaling components. Given the "natural" tendency of the BCR to undergo autoinactivation upon signal transmission, the negative feedback regulation by Ptger4 may thus shorten the activation period of the BCR, ultimately resulting in a weaker proliferative response of wild-type compared with Ptger4-deficient B cells.
###end p 39
###begin p 40
###xml 131 137 131 137 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 244 250 244 250 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 308 314 308 314 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 535 541 523 529 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 582 588 570 576 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 747 753 735 741 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTGER4</italic>
###xml 944 945 932 933 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib3">3</xref>
###xml 947 949 935 937 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib38">38</xref>
###xml 991 997 979 985 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 355 359 <span type="species:ncbi:10090">mice</span>
###xml 936 942 <span type="species:ncbi:9606">humans</span>
###xml 1090 1095 <span type="species:ncbi:10090">mouse</span>
###xml 1100 1105 <span type="species:ncbi:9606">human</span>
A striking finding of our study is the reduced in vivo tumorigenic potential of the aggressive A20 B-lymphoma cells overexpressing Ptger4. Regardless of whether the diminished tumorigenicity resulted from the enhanced cell-intrinsic effects of Ptger4, increased PGE2-EP4 signaling, or both, the over-present Ptger4 was clearly causative for protection of mice against lymphoma spread. Conversely, the aggravated symptoms caused by tumor development and the increased mortality imposed by the approximately40-45% silenced expression of Ptger4 demonstrate the inhibitory potential of Ptger4 and indicate that its deficit was, indeed, the primary genetic lesion leading to the elevated rate of tumor invasion. We were therefore not surprised to find PTGER4 significantly down-regulated in DLBCL, the most common subtype of non-Hodgkin's lymphoma that accounts for 30-40% of all lymphoma cases and that frequently shows a poor prognosis in humans (3, 38). Together, these data further establish Ptger4 as a negative regulator of BCR-signaling and identify it as a candidate tumor suppressor in mouse and human B cells.
###end p 40
###begin p 41
###xml 564 570 564 570 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 570 573 570 573 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1058 1060 1050 1052 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib18">18</xref>
###xml 1157 1159 1145 1147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib48">48</xref>
###xml 974 978 <span type="species:ncbi:10090">mice</span>
Consistent with previous reports, PGE2 potently inhibited B cell activation, and we for the first time provide definitive proof that the EP4 receptor is the principal molecule responsible for the repressive activity of PGE2 in B cells. This finding indicates that PGE2 potentiates the existing intrinsic inhibition by EP4, which is supported by the progressively greater negative influence of PGE2 on B cell proliferation and viability correlating with the expression level of EP4, and, importantly, by the reciprocal EP4-related gene regulation between activated Ptger4-/- and PGE2-treated wild-type B cells. Transcriptional profiling of PGE2-EP4 signaling uncovered a systemic down-regulation of numerous prosurvival genes that likely accounted for the impacted phenotype. Several of these genes mapped to the most significantly affected NF-kappaB pathway, indicating that the latter could play a key role in the EP4-phenotype correlation. Importantly, genetic studies in mice have confirmed the essential role of NF-kappaB in promoting B cell activation (18), and activated B cell-like DLBCL cells depend on constitutive NF-kappaB activity for survival (48). The EP4-attenuated expression of cell-cycling genes, as well as genes coding for components of the energy-producing and protein-translation machinery might have, at least in part, come as a consequence of the aberrant upstream NF-kappaB activity, together leading to a proliferation shutdown.
###end p 41
###begin p 42
###xml 484 490 484 490 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 653 655 653 655 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib21">21</xref>
###xml 676 682 676 682 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTGER4</italic>
###xml 855 857 855 857 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib22">22</xref>
Another functionally coherent network consisted of MHC class I and II members, which B cells use to present antigens to and thus stimulate T cells, thereby ensuring appropriate immune response to foreign antigens. This suggests that EP4 not only functions to negatively regulate the activation of the B cell in which it is expressed, but may also limit the responses of other immune cells in its vicinity. Nevertheless, one of the genes most significantly up-regulated by the lack of Ptger4 and repressed by PGE2-EP4 signaling, the MHC class II chaperone CD74, was found to directly stimulate B cell survival and promote malignant B cell proliferation (21). The expression of PTGER4 may thus be relevant to the efficiency of the anti-CD74 monoclonal antibody LL1, which is currently under evaluation as a novel therapeutic agent to treat B cell lymphoma (22).
###end p 42
###begin p 43
###xml 18 21 18 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYC</italic>
###xml 148 151 148 151 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYC</italic>
###xml 264 266 264 266 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib38">38</xref>
###xml 313 316 313 316 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYC</italic>
###xml 482 488 482 488 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTGER4</italic>
###xml 517 520 517 520 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYC</italic>
###xml 568 574 568 574 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTGER4</italic>
###xml 790 792 790 792 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib49">49</xref>
###xml 829 835 829 835 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTGER4</italic>
###xml 948 954 948 954 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTGER4</italic>
###xml 1070 1076 1070 1076 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTGER4</italic>
###xml 1088 1093 <span type="species:ncbi:9606">human</span>
Activation of the MYC protooncogene by chromosomal translocations or hypermutation is a key event in the pathogenesis of many B cell lymphomas, and MYC breakpoints in lymphomas with a high chromosomal complexity score strongly correlate with a poor survival rate (38). Given that the critical mechanisms by which MYC contributes to malignant transformation are not clear, it is tempting to speculate that the coordinate down-regulation of multiple tumor suppressor genes, including PTGER4, plays an important role in MYC-induced lymphomagenesis. It is noteworthy that PTGER4 has also been identified as one of a few genes targeted by the transcription factor and candidate tumor suppressor ETV6, deletions of which are observed in up to 47% of childhood pre-B acute lymphoblastic leukemia (49), implying a different mechanism of PTGER4 down-regulation in B cell malignancy. Regardless of the primary genetic lesion leading to reduced expression of PTGER4, our findings support the possibility that regulation of B cell proliferation is a contributing mechanism by which PTGER4 could hold human B cell lymphoma formation in check.
###end p 43
###begin p 44
###xml 33 39 33 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 308 314 308 314 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 431 434 431 434 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYC</italic>
###xml 470 474 470 474 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cd74</italic>
###xml 550 556 550 556 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 701 707 701 707 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 622 626 <span type="species:ncbi:10090">mice</span>
###xml 660 665 <span type="species:ncbi:9606">human</span>
Collectively, our data postulate Ptger4 as a delayed-early gene and a negative feedback regulator of BCR-signaled activation of B cells. This gene functions via its encoded EP4 receptor, which is also the principal molecule transmitting the inhibitory message of PGE2 to proliferating B cells. Regulation of Ptger4 inversely correlates with the expression of many genes that promote growth and survival of B cell lymphoma, such as MYC, members of the NF-kB pathway, and Cd74, but appears to be coordinated with several tumor suppressors. Varying the Ptger4 expression level significantly affects B cell lymphoma spread in mice and we find it down-regulated in human B cell malignancy, indicating that Ptger4 is a tumor suppressor in B cells. Finally, because EP4 is expressed as an easily accessible membrane receptor, interfering with the PGE2-EP4 signaling pathway may present a clinically useful alternative or supplement to chemotherapy in the treatment of B cell lymphoma.
###end p 44
###begin title 45
MATERIALS AND METHODS
###end title 45
###begin title 46
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice and reagents.
###end title 46
###begin p 47
###xml 79 85 79 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 85 88 85 88 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 98 104 98 104 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 104 107 104 107 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 168 170 168 170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib16">16</xref>
###xml 805 806 805 806 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 864 865 864 865 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 947 948 947 948 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 38 42 <span type="species:ncbi:10090">mice</span>
###xml 89 93 <span type="species:ncbi:10090">mice</span>
###xml 177 181 <span type="species:ncbi:10090">mice</span>
###xml 468 472 <span type="species:ncbi:10090">Mice</span>
###xml 812 817 <span type="species:ncbi:9606">human</span>
###xml 871 876 <span type="species:ncbi:10090">mouse</span>
###xml 954 959 <span type="species:ncbi:10090">mouse</span>
We obtained female C57BL/6 and BALB/c mice from The Jackson Laboratory. Female Ptger4-/- mice and Ptger4+/+ littermate controls were generated as previously described (16). All mice were housed in the Exploration and Experimental Functional Research Center (CERFE; Evry, France), and all experiments and protocols using animals were approved by the CERFE direction committee and the Institut de Radiobiologie Cellulaire et Moleculaire (CEA) animal research committee. Mice used for experiments were 8-12 wk old. PGE2, AH-13205, indomethacin, and tetracycline were purchased from Sigma-Aldrich. Prostaglandin E1 alcohol (PGE1-OH) and NS-398 were obtained from Cayman Chemical. FITC-, PE-, APC-, or biotin-conjugated antibodies to CD19, CD23, CD38, CD93, CD95, or B220 were obtained from eBioscience. F(ab')2 anti-human IgM was purchased from SouthernBiotech, F(ab')2 anti-mouse IgM was purchased from Jackson ImmunoResearch Laboratories, and F(ab')2 anti-mouse IgG was purchased from Caltag Laboratories.
###end p 47
###begin title 48
Cells, cell sorting, and culture.
###end title 48
###begin p 49
###xml 225 226 225 226 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 230 231 230 231 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 274 276 274 276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib50">50</xref>
###xml 354 355 352 353 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 473 474 470 471 <sc xmlns:xlink="http://www.w3.org/1999/xlink">l</sc>
###xml 572 573 565 566 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 768 771 760 763 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYC</italic>
###xml 977 978 968 969 <sc xmlns:xlink="http://www.w3.org/1999/xlink">l</sc>
###xml 1169 1170 1155 1156 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1391 1392 1370 1371 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 53 57 <span type="species:ncbi:10090">mice</span>
###xml 579 584 <span type="species:ncbi:10090">mouse</span>
###xml 712 717 <span type="species:ncbi:9606">human</span>
###xml 1176 1181 <span type="species:ncbi:10090">mouse</span>
###xml 1221 1226 <span type="species:ncbi:9606">human</span>
Single-cell suspensions were prepared from spleen of mice according to standard protocols. Negatively depleted B cells were recovered using B cell Isolation kit (Miltenyi Biotec) and mature B cells were further sorted as CD93-CD23+ by FACS using a MoFlo cell sorter (Dako) (50). Sorted cells were >/=95% pure. B cells were cultured at a density of 2 x 106 cells/ml in IMDM supplemented with 5% heat-inactivated FCS, 100 U/ml of penicillin, 100 mug/ml of streptomycin, 2 mM l-glutamine, and 50 muM beta-mercaptoethanol. To trigger the BCR, cells were stimulated with F(ab')2 anti-mouse IgM at 20 mug/ml. A20, a mature B lymphoma cell line of BALB/c origin (American Type Culture Collection [ATCC]), and P493-6, a human B lymphoma cell line containing a Tet-regulatable MYC gene (provided by G.W. Bornkamm, GSF Research Centre, Neuherberg, Germany) were cultivated in RPMI-1640 supplemented with 10% heat-inactivated FCS, 100 U/ml of penicillin, 100 mug/ml of streptomycin, 2 mM l-glutamine and 50 muM beta-mercaptoethanol. To inhibit the expression of MYC, P493-6 cells were incubated with 0.1 mug/ml Tet for 3 d. For BCR triggering, A20 cells were incubated with F(ab')2 anti-mouse IgG and P493-6 cells with F(ab')2 anti-human IgM, both at 20 mug/ml. NIH3T3 cells were cultivated as recommended by the ATCC. All cells were maintained at 37degreesC in a humidified atmosphere containing 5% CO2.
###end p 49
###begin title 50
Proliferation and viability assays.
###end title 50
###begin p 51
###xml 140 141 140 141 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 394 396 394 396 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib51">51</xref>
The ATP content of B cells was measured using a bioluminescence assay (ViaLight Plus; Cambrex). Tests were performed in 96-well plates at 105 cells/well according to the manufacturer's instructions. Cell cycle was analyzed using flow cytometry according to standard protocols. The CFSE method to follow B cell proliferation over time was performed according to a previously published protocol (51). Cell viability was monitored by the exclusion of 0.4% trypan blue solution visualized by light microscopy.
###end p 51
###begin title 52
Transfection and luciferase reporter assays.
###end title 52
###begin p 53
###xml 530 531 523 524 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 537 542 <span type="species:ncbi:10090">mouse</span>
A20 cells were transfected by electroporation using Nucleofector II (Amaxa Biosystems) according to the manufacturer's instructions. NF-kappaB, FOS, JUN, IL-2, EGR1, and CRE activities were measured after electroporation of cells with plasmids (2 mug) encoding the indicated response element or promoter fused to a firefly luciferase reporter gene together with the indicated Ptger4-expression vectors (2 mug) and pRL-TK as an internal control (200 ng; Promega). 48 h after transfection, cells were incubated with 20 mug/ml F(ab')2 anti-mouse IgG for 8 h, and luminescence was determined using Dual-Luciferase Reporter Assay System (Promega) according to the manufacturer's instructions. The luciferase reporter plasmids were gifts, as follows: NF-kappaB reporter plasmid from K.A. Reedquist (University of Amsterdam, Amsterdam, Netherlands), FOS and JUN reporter plasmids from H. van Dam (Leiden University, Leiden, Netherlands), IL-2 reporter plasmid from G.R. Crabtree (Stanford University, Stanford, CA), EGR1 reporter plasmid from J. Milbrandt (Washington University School of Medicine, St. Louis, MO), and CRE reporter plasmid from V.C. Manganiello (National Institutes of Health, Bethesda, MD).
###end p 53
###begin title 54
Expression vectors, lentiviruses, and stable cell lines.
###end title 54
###begin p 55
###xml 51 57 51 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 235 241 235 241 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 371 377 371 377 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 591 597 591 597 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 784 790 784 790 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 1248 1249 1248 1249 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1433 1439 1433 1439 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 45 50 <span type="species:ncbi:10090">mouse</span>
###xml 575 580 <span type="species:ncbi:10090">mouse</span>
###xml 585 590 <span type="species:ncbi:9606">human</span>
###xml 778 783 <span type="species:ncbi:10090">mouse</span>
Expression vectors to silence or overexpress mouse Ptger4 were constructed using Gateway technology and Block-iT Lentiviral Pol II miR RNAi Expression System (Invitrogen). For the silencing vectors, seven different premiRNAs targeting Ptger4 were designed using the manufacturer's RNAi Designer program, cloned into pcDNA 6.2-GW/EmGFP-miR vectors, and tested by qPCR for Ptger4 knock-down efficiency upon transfection into NIH3T3 cells with Lipofectamine 2000 (Invitrogen). The most efficient premiRNA expression cassette (miPtger4b) a less efficient cassette targeting both mouse and human Ptger4 (miPtger4a), and a nontargeting control cassette (miCTRL) were selected and recombined into pLenti6/V5-DEST destination vector. For the overexpression construct, the ORF region of mouse Ptger4 was amplified by PCR from total cDNA of A20 cells and transferred into pLenti6/V5-DEST vector. Lentiviruses were generated by cotransfecting each recombined destination vector with ViraPower packaging mix (Invitrogen) into 293FT cells as recommended by the manufacturer. A20 and P493-6 cell lines stably expressing silencing or control cassettes were generated by in vitro transduction with the appropriate lentiviral particles, followed by selection of GFP+ cells by FACS at 12 d after transduction. Similarly, A20 cells with stably integrated overexpressing cassette were generated using the blasticidin-selection method. The expression of Ptger4 in stable cells lines was verified by qPCR and immunoblotting. All synthetic oligonucleotide sequences used are listed in Table S3 (available at ).
###end p 55
###begin title 56
###xml 39 43 <span type="species:ncbi:10090">mice</span>
Lymphoma injection and immunization of mice.
###end title 56
###begin p 57
###xml 453 459 453 459 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 459 462 459 462 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 853 854 848 849 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 858 861 853 856 <sup xmlns:xlink="http://www.w3.org/1999/xlink">low</sup>
###xml 865 869 860 864 <sup xmlns:xlink="http://www.w3.org/1999/xlink">high</sup>
###xml 877 879 872 874 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib52">52</xref>
###xml 85 89 <span type="species:ncbi:10090">mice</span>
###xml 154 158 <span type="species:ncbi:10090">mice</span>
###xml 463 467 <span type="species:ncbi:10090">mice</span>
###xml 569 576 <span type="species:ncbi:9031">chicken</span>
###xml 721 725 <span type="species:ncbi:10090">mice</span>
Cells of each generated A20 stable cell line were intravenously injected into BALB/c mice, and tumor development was followed over a period of 120 d. The mice were killed when they showed excessive tumor growth. GFP expression analysis by fluorescence microscopy was used to validate the mutated A20-origin of tumors. The results are presented as Kaplan-Meier survival curves. To analyze GC B cell development in response to a T cell-dependent antigen, Ptger4-/- mice and wild-type controls were injected intraperitoneally with 100 mug of 4-hydroxy-3-nitrophenylacetyl chicken gamma-globulin (NP-CGG; Biosearch Technologies) mixed with Imject Alum (Thermo Fisher Scientific) as an adjuvant. At day 14 after immunization, mice were killed and GC B cell content in splenic single-cell suspensions was determined by flow cytometry as the percentage of CD19+CD38lowCD95high cells (52). This strategy was also used to sort wild-type GC and naive B cells for the immunoblot analysis.
###end p 57
###begin title 58
Microarray analysis.
###end title 58
###begin p 59
###xml 183 185 171 173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib53">53</xref>
###xml 508 510 496 498 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib54">54</xref>
###xml 767 773 755 761 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 773 776 761 764 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 781 787 769 775 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 787 790 775 778 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 874 876 862 864 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib55">55</xref>
###xml 995 997 983 985 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib55">55</xref>
###xml 170 175 <span type="species:ncbi:10090">mouse</span>
###xml 293 297 <span type="species:ncbi:10090">mice</span>
###xml 840 845 <span type="species:ncbi:10090">mouse</span>
For the initial screen to identify negative regulators of B cell proliferation, we used microarrays containing 15,247 cDNA clones for the analysis of approximately11,000 mouse genes (53). RNA was isolated from BCR-stimulated or vehicle-treated mature B cells from pooled spleens of 10 C57BL/6 mice using Trizol reagent (Invitrogen), followed by one round of amplification with MessageAmp kit (Ambion). The amplified RNA was reverse-transcribed, labeled, and hybridized to the arrays as previously described (54). Each sample was hybridized to the arrays in 6 replicates using a dye-swap strategy. Slides were scanned with Genepix 4000B array scanner and feature extraction was performed with Genepix Pro 6.0 software (Axon Instruments). For transcriptome analysis of Ptger4-/- and Ptger4+/+ control B cells, microarrays with 24,109 spotted mouse oligonucleotides were used (55). RNA was isolated using RNeasy Mini kit (QIAGEN), amplified, labeled, and hybridized following a published protocol (55). Oligonucleotide arrays were scanned with Agilent G2565AA Microarray Scanner (Agilent Technologies). Data analysis, including intensity-dependent Lowess normalization of raw data, was performed with GeneSpring 7.0 software (Silicon Genetics). Ingenuity Pathway Analysis (Ingenuity Systems) was used for gene ontology and network analysis.
###end p 59
###begin title 60
Real-time quantitative PCR.
###end title 60
###begin p 61
###xml 388 393 388 393 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Hprt1</italic>
Total RNA was isolated using RNeasy Mini kit, and reverse-transcribed by Superscript II Reverse transcription (Invitrogen) according to the manufacturers' protocols. Samples were processed on ABI PRISM 7700 Sequence Detection System (Applied Biosystems) using SYBR Green JumpStart Taq ReadyMix (Sigma-Aldrich). All experiments were performed in triplicate, and results were normalized to Hprt1 expression levels. Primer sequences are listed in Table S3.
###end p 61
###begin title 62
Immunoblot analysis and immunofluorescence.
###end title 62
###begin p 63
###xml 424 429 <span type="species:ncbi:10090">mouse</span>
Total cell protein extracts were prepared from B cells by lysis in RIPA Buffer supplemented with Protease Inhibitor Cocktail (both from Sigma-Aldrich). Proteins were separated by SDS-PAGE and immunoblots were performed using anti-EP4 (C-term; Cayman Chemical) and anti-actin (Sigma-Aldrich) antibodies. Immunoblots were developed with SuperSignal ECL reagent (Thermo Fisher Scientific). Immunofluorescence of BCR-stimulated mouse B cells was done using anti-EP4 antibody (C-18; Santa Cruz Biotechnology) following the manufacturer's protocol. To assure specificity of staining, anti-EP4 antibody was preincubated with fivefold (by weight) excess of the specific EP4 blocking peptide (Santa Cruz Biotechnology) for 1 h at room temperature. Indirect detection of EP4 was performed using secondary FITC-conjugated antibody.
###end p 63
###begin title 64
Measurement of PGE2 production.
###end title 64
###begin p 65
###xml 108 109 108 109 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 0 5 <span type="species:ncbi:10090">Mouse</span>
Mouse B lymphocyte culture supernatants were harvested at 0, 2, and 4 d of coincubation with anti-IgM F(ab')2 with or without indomethacin (20 muM) or NS-398 (10 muM), and analyzed by a highly specific competitive enzyme immunoassay (Prostaglandin E2 EIA kit; Cayman Chemical) to determine the concentration of PGE2. The levels of PGE2 in all samples of culture supernatants were below the detection limit of the assay (15 pg/ml). Three independent experiments were performed.
###end p 65
###begin title 66
Statistical analysis.
###end title 66
###begin p 67
###xml 129 130 127 128 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
Results are mean values +/- SD. Statistical analyses were performed using the logrank test, Wilcoxon rank sum test, or Student's t test (Oncomine), as indicated. P values of 0.05 or less were considered significant, and exact P values are shown in the figures.
###end p 67
###begin title 68
Accession nos.
###end title 68
###begin p 69
The complete microarray datasets are available from the Gene Expression Omnibus ( and ).
###end p 69
###begin title 70
URLs.
###end title 70
###begin p 71
Ingenuity Pathway Analysis: ; Oncomine database: ; Pubmed database: .
###end p 71
###begin title 72
Online supplemental material.
###end title 72
###begin p 73
###xml 571 577 571 577 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 648 654 648 654 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 901 907 901 907 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 937 943 937 943 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 989 995 989 995 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 995 998 995 998 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1014 1020 1014 1020 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptger4</italic>
###xml 1020 1023 1020 1023 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 1082 1083 1081 1082 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 319 324 <span type="species:ncbi:10090">mouse</span>
###xml 615 619 <span type="species:ncbi:10090">mice</span>
Fig. S1 shows that EP4 protein is expressed at low levels in quiescent B cells and is induced upon BCR triggering. Fig. S2 shows that BCR-triggering induces expression of the EP4 receptor on the plasma membrane of B cells. Fig. S3 shows that COX inhibition has no effect on proliferation or viability of BCR-stimulated mouse B cells. Fig. S4 shows that Ptger4 expression does not affect the BCR-induced transcriptional activity of EGR1 or transcription through CRE. Fig. S5 shows that PGE2 diminishes the viability of BCR-activated B cells in culture. Fig. S6 shows that Ptger4 antagonizes GC B cell development in mice. Table S1 shows the lack of Ptger4 facilitates BCR-triggered induction of activating genes. Tabe S2 shows genes that are induced when EP4 is absent are repressed when EP4 is abundant and activated. Table S3 shows synthetic oligonucleotide sequences used for qPCR, amplification of Ptger4 ORF region, and knockdown of Ptger4 expression. The videos show freshly isolated Ptger4-/- (Video S1) and Ptger4+/+ (Video S2) splenic B cells cotreated with 20 mug/ml F(ab')2 anti-IgM and 10 nM PGE2 in culture. Online supplemental material is available at .
###end p 73
###begin p 74
We thank P. Vaigot for help with FACS analyses and cell sorting; M.A. Zanta-Bousiff for lentivirus production; K.A. Reedquist, H. van Dam, J. Milbrandt, G.R. Crabtree, and V.C. Manganiello for reporter plasmids; G.W. Bornkamm for the P493-6 cell line, and P. Delis for animal care.
###end p 74
###begin p 75
J. Muen was supported by EGIDE.
###end p 75
###begin p 76
The authors have no conflicting financial interests.
###end p 76

